EFFECT OF ROSUVASTATIN ON CAROTID INTIMAMEDIA THICKNESS IN PATIENTS WITH CORONARY ARTERY DISEASE OF DIFFERENT GENDER AND CARDIOVASCULAR RISK PROFILE

Secondary prevention in patients with coronary artery disease (CAD) is provided by the use of statins, as well as by the impact on modiable risk factors. Rosuvastatin causes the regression of intima-media thickness (IMT) of common carotid artery (CCA), which is signicantly associated with CAD. The aim of the study was to evaluate the change in carotid intima-media thickness (CIMT) in patients with CAD of different gender, and having different number of cardiovascular risk factors, provided that patients attain target levels of total cholesterol (TC<4.0 mmol/l) and low density lipoprotein-cholesterol (LDL-C><1.8 mmol/l). Materials and methods. 72 patients with CAD: Stable angina of functional Classes II–III were recruited. They were treated with rosuvastatin, with gradual increase of its dose from 5 to 40 mg daily to attain target levels of TC and LDL-C. Maximum CIMT was assessed at the time of inclusion into the study and after 12 months of therapy. Results and discussion. In conditions of attaining target TC and LDL-C levels, maximum CIMT signi cantly decreased both in men (p=0,006) and in women (p=0,002), the latter had lower CIMT (p=0,03) than men after 1 year of therapy, taking into account no difference in baseline values. The patients who had 2 or fewer risk factors (RF) (hypertension, a family history of cardiovascular disease, smoking, obesity, diabetes mellitus were taken into consideration) showed decrease in CIMT (p=0.0001), and those who were characterized by 3 or more RF, showed only lack of its growth (p=0.07). Attained lipid levels in the compared groups of different gender and number of RF did not differ. Conclusion. The study revealed the differences in the change of CIMT in patients with CAD of different sex, and of different number of cardiovascular risk factors. Keywords: coronary artery disease, rosuvastatin, carotid intima-media thickness, gender, cardiovascular risk factor ><4.0 mmol/l) and low density lipoprotein-cholesterol (LDL-C<1.8 mmol/l). Materials and methods. 72 patients with CAD: Stable angina of functional Classes II–III were recruited. They were treated with rosuvastatin, with gradual increase of its dose from 5 to 40 mg daily to attain target levels of TC and LDL-C. Maximum CIMT was assessed at the time of inclusion into the study and after 12 months of therapy. Results and discussion. In conditions of attaining target TC and LDL-C levels, maximum CIMT signicantly decreased both in men (p=0,006) and in women (p=0,002), the latter had lower CIMT (p=0,03) than men after 1 year of therapy, taking into account no difference in baseline values. The patients who had 2 or fewer risk factors (RF) (hypertension, a family history of cardiovascular disease, smoking, obesity, diabetes mellitus were taken into consideration) showed decrease in CIMT (p=0.0001), and those who were characterized by 3 or more RF, showed only lack of its growth (p=0.07). Attained lipid levels in the compared groups of different gender and number of RF did not differ. Conclusion. The study revealed the differences in the change of CIMT in patients with CAD of different sex, and of different number of cardiovascular risk factors.

1. Karlson BW, Palmer MK, Nicholls SJ, Barter PJ, Lundman P. Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. Atherosclerosis. 2017;265:54-9. DOI: 10.1016/j. atherosclerosis.2017.08.014

2. Arutyunov AG, Arutyunov GP. Korrektsiia statinami serdechno-sosudistogo riska. Problemy i nereshennye vo-prosy na sovremennom etape [Correction of cardiovascular risk with statins. Challenges and unsolved issues at the current stage]. Russian Heart Journal. 2015;14(4):193–212. DOI: 10.18087/rhj.2015.4.2093. Russian.

3. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010 Dec 14;56(25):e50-103. DOI: 10.1016/j.jacc.2010.09.001

4. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel’iu pro laktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii. V peresmotr. [Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations. Revision V]. Russian Journal of Cardiology. 2012;96(4) (Suppl. 1). Russian.

5. Łoboz-Rudnicka M, Jaroch J, Bociąga Z, Rzyczkowska B, Uchmanowicz I, Polański J, Dudek K, Szuba A, Łoboz-Grudzień K. Impact of cardiovascular risk factors on carotid intima-media thickness: sex differences. Clin Interv Aging. 2016;11:721-31. DOI: 10.2147/CIA.S103521

6. Li X, Liu M, Sun R, Zeng Y, Chen S, Zhang P. Atherosclerotic coronary artery disease: The accuracy of measures to diagnose preclinical atherosclerosis. Exp Ther Med. 2016;12(5):2899-902. DOI: 10.3892/etm.2016.3710

7. Baroncini LAV, de Castro Sylvestre L, Filho RP. Carotid intima-media thickness and carotid plaque represent different adaptive responses to traditional cardiovascular risk factors. Int J Cardiol Heart Vasc. 2015 Aug 8;9:48-51. doi: 10.1016/j.ijcha.2015.08.003

8. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E. Comparison of the Ef cacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR* Trial). Am J Cardiol 2003;92(2):152-60.

9. Drapkina OM, Chernova EM. Miopatiia kak pobochnyi effekt terapii statinami: mekhanizmy razvitiia i perspektivy lecheniia [Myopathy as a side effect of statin therapy: mechanisms of development and prospects for treatment]. Ration Pharmacother Cardiol 2015;11(1):96-101. Russian.

10. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, Waagstein F, Wedel H, Wess-man P, Wikstrand J; CORONA Study Group. A statin in the treatment of heart failure? Controlled rosuvasta-tin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005;7(6):1059-69.

11. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61. DOI: 10.1056/NEJMoa0706201

12. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-53. DOI: 10.1001/jama.297.12.1344

13. Ballantyne CM, Raichlen JS, Cain VA, Nicholls SJ, Nissen SE; Erbel R, Tardif JC, Brener SJ, ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117(19):2458-66. DOI: 10.1161/CIRCULATIONAHA.108.773747

14. Puri R, Libby P, Nissen SE, Wolski K, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Tuzcu EM, Nicholls SJ. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014 Apr;15(4):380-8. DOI: 10.1093/ehjci/jet251

15. Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. JACC Cardiovasc Imaging. 2014 Oct;7(10):1013-22. DOI: 10.1016/j. jcmg.2014.04.019

16. Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, King P, Nicholls SJ. Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. Circ Cardiovasc Imaging. 2016 Aug;9(8). pii: e004506. DOI: 10.1161/CIRCIMAGING.116.004506

17. Persson L, Henriksson P, Westerlund E, Hovatta O, Angelin B, Rudling M. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp (a) or bile acid synthesis in women. Arterioscler Thromb Vasc Biol. 2012;32(3):810–4.

18. Reckless J. Addressing residual cardiovascular risk: what does the future hold? Br J Cardiol. 2012;19 (Suppl 1):1–16.

19. Balakhonova TV, Tripoten MI, Pogorelova OA. Ul’trazvukovye metody otsenki tolshchiny kompleksa in-tima-media arterial’noi stenki [Ultrasound methods of assessment of intima-media thickness of arterial wall]. SonoAce-Ultrasound. 2010;21:57-63. Russian.

20. Ul’trazvukovaia diagnostika sosudistykh zabolevanii [Ultrasound diagnostics of vascular diseases]. Kulikov VP, editor. Moscow: ООО Firma “Strom”; 2007. 512 p. Russian.

21. Ten Haaf ME, Rijndertse M, Cheng JM, de Boer SP, Garcia-Garcia HM, van Geuns RM, Regar E, Lenzen MJ, Appelman Y, Boersma E. Sex differences in plaque characteristics by intravascular imaging in patients with coronary artery disease. EuroIntervention. 2017 Jun 20;13(3):320-8. DOI: 10.4244/EIJ-D-16-00361

22. Tabatabaei-Malazy O, Fakhrzadeh H, Shari F, Mirare n M, Badamchizadeh Z, Larijani B. Gender differences in association between metabolic syndrome and carotid intima media thickness. J Diabetes Metab Disord. 2012;11(1):13. DOI: 10.1186/2251-6581-11-13

23. Karpov IuA, Sorokin EV. Faktory riska IBS: kogda i kak provodit’ korrektsiiu? Povyshenie roli statinov [CAD risk factors: when and where to provide correction? Enhancing the role of statins]. Russian Medical Journal. 2003;19:1041-5. Russian.